Russell's 2011 narrative review covers the first 40 years of bisphosphonate science, from the 1962 discovery of inorganic pyrophosphate as the body's endogenous calcification inhibitor through the elucidation of two distinct molecular mechanisms and the establishment of bisphosphonates as first-line therapy for osteoporosis, Paget's disease, and malignancy-related bone disease.
When selecting a bisphosphonate or counseling patients on side effects, the two-class framework matters clinically: nitrogen-containing BPs (alendronate, zoledronate, risedronate) are far more potent FPPS inhibitors and are responsible for the acute-phase flu-like response on first IV dosing (via γδ T-cell activation by accumulated IPP), while the narrow mineralization-to-resorption window of etidronate (only ~10-fold) explains why it fell out of favor for osteoporosis.
The lack of head-to-head trials means potency rankings from animal models and surrogate markers — not direct fracture-endpoint comparisons — guide most clinical choices.
Russell's 2011 narrative review covers the first 40 years of bisphosphonate science, from the 1962 discovery of inorganic pyrophosphate as the body's endogenous calcification inhibitor through the elucidation of two distinct molecular mechanisms and the establishment of bisphosphonates as first-line therapy for osteoporosis, Paget's disease, and malignancy-related bone disease.
When selecting a bisphosphonate or counseling patients on side effects, the two-class framework matters clinically: nitrogen-containing BPs (alendronate, zoledronate, risedronate) are far more potent FPPS inhibitors and are responsible for the acute-phase flu-like response on first IV dosing (via γδ T-cell activation by accumulated IPP), while the narrow mineralization-to-resorption window of etidronate (only ~10-fold) explains why it fell out of favor for osteoporosis.
The lack of head-to-head trials means potency rankings from animal models and surrogate markers — not direct fracture-endpoint comparisons — guide most clinical choices.